• AEON Biopharma received NYSE American notice confirming it regained compliance with continued listing standards tied to stockholders’ equity.
• NYSE American cited resolution of deficiencies under Sections 1003(a)(i) and 1003(a)(ii); the “.BC” trading indicator is expected to be removed.
• Compliance followed a July 2026 underwritten offering that generated about USD 13.6 million in net proceeds, lifting equity above the USD 4 million minimum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001837607-26-000057), on August 03, 2026, and is solely responsible for the information contained therein.